Announcements

favicon.png
- Findings of IVI-led study in 10 African countries published in The Lancet Global Health - High disease burden findings support the introduction of typhoid conjugate vaccines in high-incidence settings     February 27, 2017 - An IVI-led study found that typhoid fever and invasive non-typhoidal Salmonella (iNTS) disease are major causes of invasive bacterial febrile illness in some African countries, and they most commonly afflict children in low and high population density settings.   Large variations exist in the disease burden of Salmonella Typhi and non-typhoidal Salmonella in sub-Saharan Africa, with rates of disease reaching as high as 383 per 100,000 persons per years (PY) for S. Typhi and 237 per 100,000 PY for iNTS disease in Burkina Faso. A rate of more than 100 per 100,000 is considered “high” as defined by the World Health Organization (WHO). Typhoid was found in both infants and school-age children, with a higher incidence in children below 15 years old, according to the study recently published in The Lancet Global Health.   The varying incidence of disease-causing Salmonella suggests a complex epidemiology and a highly diverse disease distribution pattern in sub-Saharan Africa. Worryingly, significant levels of multidrug resistance were found in S. Typhi and iNTS strains in several settings. The findings support the rationale for the development and deployment of new vaccines against typhoid and iNTS disease.   “The development of iNTS vaccines and the introduction of S. Typhi conjugate vaccines currently under clinical development should be considered for high-incidence settings, such as those identified in this study,” said Dr. Florian Marks, IVI senior scientist and lead investigator of the study. Typhoid fever is a relatively common disease in many low- and middle-income countries where clean water and basic sanitation facilities are scarce. The disease is characterized by chronic fever that can lead to serious complications including intestinal perforation or neurological problems if untreated. It is estimated there are more than 20 million cases of invasive Salmonella infections globally, most of which are caused by S. Typhi, and 200,000 to 600,000 deaths per year.   While previous evidence suggested typhoid is a public health problem in Africa, there was limited scientific data to back up those claims. Consequently, IVI, with a network of partners, conducted the Typhoid Fever Surveillance in Africa Program (TSAP), the first multi-country population-based typhoid surveillance study in Africa. TSAP, which ran from 2011 to 2014, aimed to measure the incidence of typhoid fever and iNTS disease in sub-Saharan Africa, as well as the antimicrobial susceptibility of these causative agents. The program was funded by the Bill & Melinda Gates Foundation.   IVI established a standardized surveillance network for invasive bacterial bloodstream infections consisting of 13 field sites in ten sub-Saharan African countries. Blood cultures were conducted on a total of 13,431 febrile patients. The study found the incidence rates of S. Typhi ranged from 0 per 100,000 person-years in Sudan to 383 per 100,000 PY in Burkina Faso; while the incidence of iNTS ranged from 0 in Sudan, Ethiopia, Madagascar, and South Africa to 237 per 100,000 in Burkina Faso. The Salmonella spp. strain accounted for 33% or more of all bacterial pathogens at nine sites.   Multidrug-resistant S. Typhi was isolated at sites in Ghana, Kenya, and Tanzania, and multidrug-resistant iNTS was isolated at sites in Burkina Faso, Ghana, Kenya, and Guinea-Bissau.   “A key challenge is to determine how useful an efficacious vaccine might be in low to middle-income countries, where the levels of disease vary so greatly between different regions. Such studies might be pivotal to facilitate the deployment of such vaccines,” Prof. Gordon Dougan of the Wellcome Trust Sanger Institute said in his comment in The Lancet Global Health. “The changing epidemiological pattern, the emergence of a potentially more aggressive multidrug resistant strains, and the likelihood of increased antibiotic usage in communities affected by the disease are creating a sense of urgency (for the development and subsequent deployment of vaccines).”   Building upon these findings, IVI scientists are currently investigating severe typhoid cases in Africa by collecting additional information such as long-term manifestations of illness and socio-economic burden. This new program, Severe Typhoid in Africa (SETA), is also funded by the Bill & Melinda Gates Foundation. Such novel evidence will help strengthen the case for disease prevention and control measures, including the development and introduction of new vaccines.
favicon.png
Study finds a window of opportunity for CD8+ T cells to reduce overall number of HIV-infected cells   A new study has shown that potent HIV-specific CD8+ T cells that are able to kill HIV-producing cells and reduce the seeding of the HIV reservoir are only detected at peak viremia in acute HIV infection. Findings from the study, which was led by the U.S. Military HIV Research Program (MHRP) of the Walter Reed Army Institute of Research, were recently published in Science Translational Medicine.   HIV-specific CD8+ T cells are white blood cells that kill cells infected with HIV.  CD8+ T cells play a critical role in controlling HIV viremia and could be important in reducing overall numbers of HIV-infected cells in approaches to eradicate HIV.   Researchers tracked immune response through three distinct acute HIV infection (AHI) stages. They found that the HIV-specific CD8+ T cells generated during AHI stage 1 and 2, prior to peak viremia, are delayed in expanding and acquiring effector functions, meaning they are less effective at controlling HIV replication. The viral reservoir poses a critical challenge in the quest to cure HIV infection since it contains cells in which the HIV virus can lie dormant for many years, thereby avoiding elimination by antiretroviral therapy   Prior to his tenure as IVI Director General, Dr. Jerome H. Kim was the Principal Deputy and Chief of the Laboratory of Molecular Virology and Pathogenesis at MHRP and Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Material Development Activity. From 2004 to 2009, he led the Army's Phase III HIV vaccine trial (RV144), the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates of protection and sequence changes in breakthrough HIV infections after vaccination.   For more information about the study, please visit: http://www.hivresearch.org/news/new-study-provides-clues-early-t-cell-immune-responses-acute-hiv-infection
IMG_4942.jpg
S.-Japan Cooperative Medical Sciences Program’s (USJCMSP) 19th International Conference on Emerging Infectious Diseases (EID) in the Pacific Rim runs from Feb. 7 to 10 First time conference held in South Korea; the International Vaccine Institute is the local host  February 7, 2017, Seoul, Korea – The “U.S.-Japan Cooperative Medical Sciences Program (USJCMSP) 19th International Conference on Emerging Infectious Diseases (EID) in the Pacific Rim” kicked off its first day at the Novotel Ambassador Seoul Gangnam.  Held for the first time in South Korea, the International Vaccine Institute (IVI) is the local host of the four-day conference, which runs from February 7-10. Since 1996, the United States-Japan Cooperative Medical Sciences Program has been convening the EID conference annually in alternating countries. It serves as a venue for panel meetings and discussion of cross-cutting topics related to infectious disease research to promote international cooperation in research efforts in response to new, emerging infectious disease challenges of Asia and the greater Pacific region.   The conference draws researchers, government and public health officials, and representatives from academia and other public and private institutions from Pacific Rim countries such as South Korea and Japan, and the United States. More than 300 people from over 20 countries are participating this year, and speakers include researchers from the National Institute of Allergy and Infectious Diseases (NIAID), USA; Yonsei University; National Cancer Center, Korea; Harvard University; Hokkaido University Research Center for Zoonosis Control, Japan; China Agricultural University; and National Institute of Infectious Diseases (NIID), Japan among many others.   This year’s conference focuses on antimicrobial resistance of bacterial and parasitic diseases of importance in the Asia-Pacific region. In addition, panels on Acute Respiratory Infections (ARI), Cancer, Cholera and Other Bacterial Enteric Infections, Mycobacteria, and Parasitic Diseases present the latest research in these disease areas. Oral and poster presentations will be given at the conference and disease panel workshops over the four days.   “As the local host and co-sponsor this year, we are very pleased to be a part of this major international scientific conference in the Asia-Pacific region,” said Jerome Kim, IVI Director General, “The program features discussions and presentations by scientific experts from around the world who will share latest research findings related to antimicrobial resistance, a timely and pressing topic in global health.” Among the speakers providing welcome remarks on the first day were Marc Knapper, Chargé d'Affaires, US Embassy in Seoul; Hideo Suzuki, Chargé d'Affaires ad interim, Embassy of Japan in Seoul; Jerome Kim, Director General of IVI; Aikichi Iwamoto, Science and Technology Advisor, Japan Agency for Medical Research and Development (AMED); and Patrick Brennan, University Distinguished Professor, Colorado State University   The conference was co-sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), the Japanese Ministries of Health, Labor and Welfare (MHLW) and Education, Culture, Sports, Science and Technology (MEXT), the Japan Agency for Medical Research and Development (AMED), and IVI.  Support was also provided by the Bill & Melinda Gates Foundation.         ###  About IVI The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.  Media Contact:  IVI Tae Kyung Byun Phone: +82-2-872-2801 (Ext. 159) Mobile: +82-11-9773-6071 Email: tkbyun@ivi.int
favicon.png
IVI is pleased to announce that India will become a financially contributing member state, providing USD 500,000 per year to IVI. The Indian Cabinet, chaired by Prime Minister Shri Narendra Modi, recently approved the proposal. India will be the third member state to provide annual funding to the Institute, in addition to Korea and Sweden. The Indian funding will support IVI operations, vaccine R&D and capacity-building projects in India. IVI and India have a long history of collaboration. In 2007, India became a signatory to IVI’s treaty that comprises of 35 signatory countries and the World Health Organization (WHO). For many years, IVI has been partnering with various Indian vaccine manufacturers, research institutes, government, and public health agencies such as Shantha Biotechnics, National Institute of Cholera and Enteric Diseases (NICED), and the Indian Council for Medical Research (ICMR) on product development partnership, research, and training. One of the most successful collaborations was the development and WHO prequalification of the inactivated oral cholera vaccine, Shanchol, in 2011, the world’s first affordable oral cholera vaccine for global public health. The new development will strengthen already close ties by promoting further synergies between IVI and India on vaccine development and public health research. The partnership will enable IVI to exert a greater impact in vaccine development and delivery, particularly in India. An official signing ceremony between the two parties is being planned. More information about the ceremony and agreement will follow soon.
favicon.png
The U.S.-Japan Cooperative Medical Sciences Program’s 19th International Conference on Emerging Infectious Diseases (EID) and associated Workshop on Cholera and Other Bacterial Enteric Infections will be on February 7-10, 2017 at the Novotel Seoul Ambassador Gangnam Hotel. Organized by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), the Japanese Ministries of Health, Labor and Welfare (MHLW) and Education, Culture, Sports, Science and Technology (MEXT), and the Japan Agency for Medical Research and Development (AMED), IVI is the local host of this year’s conference. Since 1996, the United States-Japan Cooperative Medical Sciences Program has been convening the EID conference annually in alternating countries. It serves as a venue for panel meetings and discussion of cross-cutting topics related to infectious disease research to promote international cooperation in research efforts in response to new, emerging infectious disease challenges of Asia and the greater Pacific region. Participants include researchers, government and public health officials, and representatives from academia and other public and private institutions from countries within the Pacific Rim region, including Korea, Japan, and the United States. For more information about EID and the Workshop, please visit: https://respond.niaid.nih.gov/conferences/USJapanCMSP2017/Pages/default.aspx https://respond.niaid.nih.gov/conferences/usjapancmsp/Pages/Cholera-Panel.aspx To register: https://respond.niaid.nih.gov/conferences/USJapanCMSP2017/Pages/Registration.aspx
favicon.png
Campaign to vaccinate about 27,000 people to prevent endemic cholera IVI Director General commends Rotary’s leadership and support, announces intent to provide additional vaccinations in developing countries through international collaboration The International Vaccine Institute (IVI), Rotary International (District 3640, District 3710), Rotary Club of Seoul Southwest in Korea, and Rotary Club of Nagarjun in Nepal announced on January 9 their global health partnership that recently completed vaccination of about 27,000 people at risk of cholera in Nepal. The vaccinations has been conducted in Banke, an area in southwest Nepal that borders with India, to protect people against cholera, a potentially fatal and highly contagious diarrheal disease. Cholera is endemic in Nepal, and people in the area are at high risk of cholera due to lack of clean water and limited sanitation and hygiene. The vaccination campaign used a two-dose oral cholera vaccine, developed by IVI through a public-private partnership with groups that include the Bill & Melinda Gates Foundation and the governments of Korea and Sweden. Notably, the vaccine ‘Euvichol’ is produced by the Korean vaccine manufacturer EuBiologics who worked with IVI on its development and production following technology transfer from IVI. The vaccine is prequalified by the World Health Organization and is the first Korean-made cholera vaccine for global public health. To ensure the vaccine reaches vulnerable populations, IVI collaborated with Rotary International and Nepalese health authorities to conduct the vaccination campaign, targeting residents one year old and up.  The first round occurred on early December, and the second round in mid- to late December. The vaccination campaign was led by Rotary Club of Seoul Southwest and International Rotary Districts 3640 and 3710, and was supported through a Global Grant from the Rotary Foundation. Collaborators in Nepal included the Nepalese Ministry of Health, Group for Technical Assistance (GTA), and other partners. The campaign was also supported by a number of Korean donors, including the Export Import Bank of Korea, the Kim & Chang CSR Committee, and Sartorius Korea Biotech. The campaign followed previous efforts by IVI to deliver cholera vaccines in Nepal, which has annual cholera outbreaks. The situation was exacerbated due to the earthquakes in 2015 that destroyed the health infrastructure in some remote parts of the country.  In 2015, the Institute conducted emergency vaccinations in Nuwakot and Dhading to contain sporadic cholera cases from spreading in the aftermath of the earthquakes. IVI Director General Dr. Jerome Kim said, “Through a collaboration with Rotary and with support from donors, we were able to provide much-needed protection to people in cholera-prone areas in Nepal,” adding, “We hope this project will be the starting point to expand our partnership with Rotary International who successfully spearheaded the Global Polio Eradication Initiative with other partners.” “Thanks to great support from our donors in Korea and elsewhere, we have been able to deliver vaccines to needy populations at risk of cholera,” Dr. Kim said, “We hope to see continued support from companies and donors in Korea so that we can protect more people against cholera.” IVI, Korea Support Committee for IVI, and Rotary District 3640 exchanged a three-way memorandum of understanding in September this year with the view to conducting joint vaccination projects to prevent cholera among children in developing countries.       ###   About IVI The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.
favicon.png
- IVI to serve as local host and co-sponsor The U.S.-Japan Cooperative Medical Sciences Program’s 19th International Conference on Emerging Infectious Diseases (EID) and associated Workshop on Cholera and Other Bacterial Enteric Infections will be on February 7-10, 2017 at the Novotel Seoul Ambassador Gangnam Hotel. Organized by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), the Japanese Ministries of Health, Labor and Welfare (MHLW) and Education, Culture, Sports, Science and Technology (MEXT), and the Japan Agency for Medical Research and Development (AMED), IVI is the local host of this year’s conference. Since 1996, the United States-Japan Cooperative Medical Sciences Program has been convening the EID conference annually in alternating countries. It serves as a venue for panel meetings and discussion of cross-cutting topics related to infectious disease research to promote international cooperation in research efforts in response to new, emerging infectious disease challenges of Asia and the greater Pacific region. Participants include researchers, government and public health officials, and representatives from academia and other public and private institutions from countries within the Pacific Rim region, including Korea, Japan, and the United States. For more information about EID and the Workshop, please visit: https://respond.niaid.nih.gov/conferences/USJapanCMSP2017/Pages/default.aspx https://respond.niaid.nih.gov/conferences/usjapancmsp/Pages/Cholera-Panel.aspx Planning is in process and more information about the conference will be provided shortly.
forum_3.jpg
International meeting convenes leading scientists and experts to accelerate development of vaccines against group A Streptococcus (GAS) GAS is a potentially deadly bacterial pathogen, causing rheumatic heart disease and invasive infection in developing countries December 13, 2016, Seoul, Korea – The International Vaccine Institute (IVI) and the World Health Organization (WHO) are co-hosting the Global Stakeholder Consultation on Group A Streptococcal (GAS) Vaccine Development at the Sheraton Seoul Palace Gangnam Hotel from December 12-13. The one-and-a-half-day meeting convenes international scientific experts, vaccine developers and funders to review evidence on GAS burden of disease and the need for a vaccine, and to discuss the feasibility and pathway for developing GAS vaccines.  The meeting is in line with WHO’s goal to accelerate the development and licensure of high-quality, safe and effective GAS vaccines for low-and middle-income countries. Group A Streptococcus (Streptococcus pyogenes) is a bacterial pathogen that causes a broad spectrum of disease ranging from mild infections such as strep throat that lead to progressive heart damage and death. The disease is often associated with lower development status and poverty, and is commonly found in Africa, the Subcontinent, the islands of the Pacific, and among the First Nations of Canada, the native peoples of Australia and New Zealand, and native Americans. The WHO estimates GAS causes a substantial burden of disease and death globally, especially in low and middle-income countries where rheumatic heart disease and invasive infections are common. Globally over 400,000 people die every year from complications of infection. A vaccine is currently not available. Speakers and participants include representatives from organizations such as PATH, Wellcome Trust, Prevent Canada, US Centers for Disease Control and Prevention, GSK, Pfizer, Sanofi, London School of Hygiene & Tropical Medicine, University of Auckland, Murdoch Children’s Research Institute, University of Queensland, University of Melbourne, and University of Hawaii among others. Her Excellency Clare Fearnley, the New Zealand Ambassador to Korea, and Mr. Ravi Kewalram, Chargé d'Affaires of the Australian Embassy Seoul gave opening remarks on the first day. The meeting is supported by Shinil, the Coalition to Advance New Vaccines against group A Streptococcus (CANVAS), RHD Action, and the Murdoch Children’s Research Institute.  It is also the second in a series of annual global vaccine fora organized by IVI and supported by Shinil. “The consultation provides an excellent opportunity to discuss, coordinate and mobilize resources and action at a global level to take concerted action against group A Streptococcus,” said Jerome Kim, IVI Director General, “The increasing body of evidence shows that the burden of GAS diseases and its linkage with poverty cannot be ignored. The global health community must work together to accelerate the development of a vaccine against this major killer.” ###   About IVI The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int. Media Contact: IVI Tae Kyung Byun Phone: +82-2-872-2801 (Ext. 159) Mobile: +82-11-9773-6071 Email: tkbyun@ivi.int
favicon.png
Every year around the world, up to 4 million people are diagnosed with cholera, an acute diarrheal disease that’s usually spread through contaminated water in developing countries. In the long term, advances in water supply and sanitation are thought to be the ideal way to control the spread of the disease, but a handful of vaccines have also been developed—or are in development—to prevent cholera. Now, researchers have described, in PLOS Neglected Tropical Diseases, a standardized method to analyze the full costs for the implementation and delivery of cholera vaccines in low and middle income countries. The approach, they hope, will be a boon to programs planning or reviewing vaccination efforts. In the new work, Vittal Mogasale, of International Vaccine Institute, South Korea, and colleagues reviewed ten previous papers outlining cholera vaccine programs in low and middle income countries—those with a gross national income per capita of $4,035 or less. For each vaccine deployment, costs described in the previous papers were categorized into four groups: vaccination program preparation, vaccine administration, adverse events following immunization, and vaccine procurement. Within each group, costs for various subgroups were also tallied. The researchers presented overall vaccination program costs as the sum of all categories, and converted the numbers from local currencies to both 2014 US dollars and 2014 international dollars. The researchers found a wide variability in costs between different cholera vaccination efforts. Vaccine delivery costs—the sum of preparation, administration, and adverse event costs—ranged from US$0.36 to US$6.32 per person vaccinated, while the vaccine procurement costs ranged from US$0.29 to US$29.70. Costs were varied even between different efforts in the same country, they found. The scale of vaccination efforts only partially explained differences. The study, offering numbers for those outlining the budgets of future efforts, was limited by the fact that the categories were not standardized from the outset and so some budget items could have been misclassified. “Understanding the costs of cholera vaccination campaigns is of paramount importance in the economic evaluation as well as in planning future vaccination programs,” the researchers conclude. “The categories described herein allow for a clear, comparative understanding of vaccination campaign costs that can better describe decision-making.” CONTACT: Vittal Mogasale International Vaccine Institute Policy and Economic Research Center, Access Department SNU Research Park, San 4-8 Nakseongdae-dong Gwanak-gu Seoul , 08826, Republic of Korea +82 2 881 1379 vmogasale@ivi.int;vmogasale@gmail.com FUNDING: This work was conducted as part of the Delivering Oral Vaccine Effectively (DOVE) Initiative (https://www.stopcholera.org/), funded by the Bill and Melinda Gates Foundation through the Johns Hopkins University Bloomberg School of Public Health (Grant CHJOH05064-010). The International Vaccine Institute received funding support from the Government of the Republic of Korea and the Government of Sweden. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. COMPETING INTERESTS: The authors have declared that no competing interests exist.
IVI GeneOne collaboration 3.jpg
IVI GeneOne collaboration 3 photo: (left to right) Joel Maslow, Chief Medical Officer of GeneOne and Young K. Park, President and CEO of GeneOne, Phil Driver, IVI Deputy Director General of Finance & Operations, and In-Kyu Yoon, IVI Deputy Director General of Science at at the signing ceremony at IVI headquarters on Dec. 6, 2017. - Parties to collaborate in clinical development of GeneOne’s DNA-based MERS-CoV vaccine - Collaboration will accelerate vaccine development and ensure access for public health readiness in case of future outbreaks in Korea and worldwide SEOUL, KOREA, 6 December, 2016 - The International Vaccine Institute (IVI) and GeneOne Life Science Inc. have agreed to collaborate in developing a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine development so that a vaccine can be available in South Korea for emergency deployment in the event of a future outbreak. IVI and GeneOne held a signing ceremony at IVI headquarters at Seoul National University Research Park on December 6, 2016, where the two parties agreed to cooperate in MERS-CoV vaccine clinical development, and to ensure vaccine access to the Korean public health sector in case of an emergency and for public health programs. In attendance were IVI CFO Phil Driver, and GeneOne CEO Young K. Park. IVI and GeneOne plan to jointly conduct a clinical trial in Korea of GeneOne’s DNA-based MERS-CoV vaccine candidate called GLS-5300. IVI will provide support for the clinical trial and conduct other related activities including technical consultation and laboratory evaluations of immune response in trial participants at its Seoul-based laboratory facilities. GeneOne additionally signed an agreement to supply GeneOne’s MERS-CoV vaccine for use in potential emergencies and public health programs in Korea. To this end, IVI and GeneOne would collaborate to obtain the necessary approvals from the Korean regulatory and health authorities. Despite the continuing threat of epidemics from this zoonotic respiratory disease, there is currently no licensed vaccine or treatment for MERS-CoV. As of 2 December 2016, the World Health Organization (WHO) reports 1,841 MERS cases and 652 (35.4%) deaths worldwide since MERS-CoV was first identified in Saudi Arabia in 2012. Since then, 27 countries have reported cases, including Korea where an outbreak took place in the summer of 2015 resulting in 186 cases and 38 deaths. GeneOne, a leading biotech company based in Korea, is developing the GLS-5300 DNA-based vaccine against MERS-CoV. GLS-5300 has been shown to prevent disease in pre-clinical animal studies. The vaccine is being evaluated in an ongoing Phase 1 clinical trial at the Walter Reed Army Institute of Research (Silver Spring, Maryland, USA) to test for safety and immune response of the vaccine. Dr. Jerome Kim, IVI Director General said, “As an international organization devoted to vaccines for global public health, IVI looks forward to partnering with GeneOne, a Korean vaccine developer and manufacturer whose vaccine looks very promising among the candidates in the MERS-CoV vaccine development pipeline worldwide,” adding, “IVI will closely work with GeneOne to accelerate the development of a MERS-CoV vaccine to increase the public health readiness of Korea and the world to effectively respond to a potential MERS outbreak.” Young K. Park CEO of GeneOne said, “GeneOne Life Science has committed to the clinical development of its MERS-CoV vaccine in the shortest possible period of time. GeneOne is a Korean company that is at the forefront of vaccine development for emerging infectious diseases. During the outbreak of MERS-CoV in our country, GeneOne committed its resources to advance a vaccine for MERS-CoV. We are hoping to be able to confront this disease that has so devastated the lives of many. This collaboration with IVI will advance vaccine development for MERS-CoV and improve outbreak readiness for Korea and worldwide.” GeneOne is developing the GLS-5300 MERS-CoV DNA vaccine with Inovio Pharmaceuticals, Inc. and academic collaborators. The GLS-5300 vaccine was manufactured at GeneOne’s subsidiary VGXI, Inc. located in the Woodlands Texas, USA. . About IVI The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int. About GeneOne Life Science, Inc. GeneOne is an international company focused on finding gene-based solutions to clinical disease. GeneOne is at the forefront of DNA vaccine and DNA-based therapeutic development. GeneOne is currently spearheading clinical trials of vaccines for the Zika virus, MERS-CoV, Ebola and other infectious diseases. GeneOne has a rich pipeline of products targeting multiple cancers and diseases of man. GeneOne’s wholly-owned subsidiary VGXI, Inc. (www.vgxii.com) has 15 years of experience in the manufacture of DNA plasmid vaccines and therapeutics and has the distinction of making vaccines for Zika, MERS-CoV, and Ebola for use in human clinical trials. GeneOne is headquartered in Seoul, South Korea. For more information, visit www.genels.com. Media Contact: IVI Tae Kyung Byun Senior Manager of Korean Communications, IVI Phone: +82-2-872-2801 (Ext. 159) Mobile: +82-10-8773-6071 Email: tkbyun@ivi.intGeneOne Life Science, Inc. James Kim General Manager Phone: +82-2-527-0609 Mobile: +82-10-6202-1396 Email: jikim@genels.com